Overview
- Preliminary revenue reached about $2.87 billion in Q4 and $10.06 billion for 2025, rising roughly 19% and 21% year over year and topping the Street’s $2.72 billion Q4 estimate.
- Worldwide procedures grew about 18% in Q4 and 19% for the full year, with Ion bronchoscopy procedures up roughly 44% from a year earlier.
- The company forecast global da Vinci procedure growth of roughly 13% to 15% in 2026, a pace reported as below some analyst expectations near 15.2% and the slowest since 2020.
- Intuitive placed 532 da Vinci systems in Q4 and 1,721 in 2025, with placement growth trailing procedure growth and signaling higher utilization of the installed base.
- Shares fell about 4% to 6% after the update, as commentary also cited China tender and pricing pressures and new competitors; official Q4 and full-year results are due Jan. 22.